nach oben

Die Kardiologie

Erschienen in:

01.06.2012 | Positionspapier

Update orale Plättchenhemmer

Positionspapier der deutschen Gesellschaft für Kardiologie

verfasst von: Prof. Dr. M. Gawaz, PD Dr. T. Geisler

Erschienen in: Die Kardiologie | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine zuverlässige und langfristige duale Plättchenhemmung bei der Behandlung von Patienten mit koronarer Stentimplantation und Patienten mit akuten Koronarsyndromen ist zur Vermeidung schwerwiegender thrombotischer Ereignisse und lebensbedrohlicher Stentthrombosen erforderlich. Neu entwickelte medikamentöse Therapieoptionen sowie gesundheitspolitische Gegenpositionen zu Therapiealgorithmen internationaler Fachgesellschaften führen zur öffentlichen Verunsicherung. Entsprechend den Leitlinien der Fachgesellschaften (ESC und AHA/ACC) muss die duale Plättchenhemmung nach akutem Koronarsyndrom („acute coronary syndrome“, ACS) unabhängig von der Akuität (STEMI oder N-STEMI) und der primären Therapie für mindestens 12 Monate bei fehlenden Kontraindikationen durchgeführt werden. Unter Abwägung des Blutungsrisikos sind neuere P2Y₁₂-Rezeptorantagonisten (Prasugrel, Ticagrelor) beim ACS nach aktuellen Leitlinien vorzuziehen. Nach elektiver Implantation unbeschichteter Koronarstents sollte Clopidogrel (Clopidogrel-Hydrogensulfat) für einen Monat und nach medikamentenfreisetzenden Stents für mindestens 6 Monate und in Abhängigkeit vom individuellen Risikoprofil für optimal 12 Monate verabreicht werden.

Baigent C, Blackwell L, Collins R et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Antithrombotic Trialists‘ (ATT) Collaboration. Lancet 373(9678):1849–1860PubMedCrossRef

Juul-Möller S, Edvardsson N, Jahnmatz B et al (1992) Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 340(8833):1421–1425PubMedCrossRef

Antiplatelet Trialists‘ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy – 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81–106CrossRef

Antithrombotic Trialists‘ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86CrossRef

Patrono C, Coller B, Dalen JE et al (2001) Platelet active drugs: the relationships among dose, effectiveness, and side effects. Chest 119:39–63CrossRef

CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038):1329–1339CrossRef

Bhatt DL, Flather MD, Hacke W et al (2007) Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49(19):1982–1988PubMedCrossRef

Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H (2004) Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (Aspirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 38(6):353–356PubMedCrossRef

Guidelines on myocardial revascularization (2010) The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 31(20):2501–2555CrossRef

10.

Kastrati A, Schömig A, Dirschinger J et al (2000) A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary stenting or angioplasty for restenosis reduction in small arteries. Circulation 102(21):2593–2598PubMedCrossRef

11.

Scheller B, Hehrlein C, Bocksch W et al (2008) Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 97:773–781PubMedCrossRef

12.

Scheller B, Levenson B, Joner M et al (2011) Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter: Positionspapier der DGK 2011. Kardiologe, doi:10.1007/s12181-011-0375-6

13.

Unverdorben M, Vallbracht C, Cremers B et al (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119(23):2986–2994PubMedCrossRef

14.

King SB III, Smith SC Jr, Hirshfeld JW Jr et al (2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117(2):261–295PubMedCrossRef

15.

Bertrand ME, Rupprecht HJ, Urban P et al (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102(6):624–629PubMedCrossRef

16.

Taniuchi M, Kurz HI, Lasala JM (2001) Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 104:539–543PubMedCrossRef

17.

Steinhubl SR, Berger PB, Mann JT III et al (2002) Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19):2411–2420PubMedCrossRef

18.

Berger PB, Mahaffey KW, Meier SJ et al (2002) Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J 143(5):841–846PubMedCrossRef

19.

Brar SS, Kim J, Brar SK et al (2008) Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 51(23):2220–2227PubMedCrossRef

20.

Iakovou I, Schmidt T, Bonizzoni E et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17):2126–2130PubMedCrossRef

21.

Stone GW, Moses JW, Ellis SG et al (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356(10):998–1008PubMedCrossRef

22.

Mauri L, Hsieh WH, Massaro JM et al (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356(10):1020–1029PubMedCrossRef

23.

Spaulding C, Daemen J, Boersma E et al (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356(10):989–997PubMedCrossRef

24.

Silber S, Albertsson P, Aviles FF et al (2005) Guidelines for percutaneous interventions: the task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 26:804–847PubMedCrossRef

25.

Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. German Cardiac Society: Positionspapier zur Vermeidung von Tod und lebensbedrohlichen Komplikatonen nach koronarer Stentimplantation durch die zusätzliche Gabe von Clopidogrel. Herausgegeben vom Vorstand der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung. Bearbeitet im Auftrag der Kommission für Klinische Kardiologie. Dtsch Ärztebl 103:A2863–A2868

26.

Bonzel T, Erbel R, Hamm CW et al (2008) Percuaneous coronary intervention (PCI). Clin Res Cardiol 97(8):513–547PubMedCrossRef

27.

Park SJ, Park DW, Kim YH et al (2010) Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362(15):1374–1382PubMedCrossRef

28.

Schulz S, Schuster T, Mehilli J et al (2009) Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 30(22):2714–2721PubMedCrossRef

29.

Airoldi F, Colombo A, Morici N et al (2007) Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116(7):745–754PubMedCrossRef

30.

Onuma Y, Serruys PW, Kukreja N et al (2010) Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. Eur Heart J 31(9):1071–1078PubMedCrossRef

31.

Eisenstein EL, Anstrom KJ, Kong DF et al (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297(2):159–168PubMedCrossRef

32.

Kandzari DE, Barker CS, Leon MB et al (2011) Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv 4:1119–1128PubMedCrossRef

33.

Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23):2999–3054PubMedCrossRef

34.

Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29(23):2909–2945CrossRef

35.

Kushner FG, Hand M, Smith SC Jr et al (2009) 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54(23):2205–2241PubMedCrossRef

36.

Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology et al (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51(2):210–247CrossRef

37.

Grines CL, Bonow RO, Casey DE Jr et al (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc 138:652–655PubMed

38.

Bhatt D, Flather M, Hacke W et al (2007) Patients with prior myocardial infarction, stroke, or symptomatic peripheral artery disease in the CHARISMA trial. J Am Coll Cardiol 49:1982–1988PubMedCrossRef

39.

COMMIT Collaborative Group (2005) Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised, placebo-controlled trial. Lancet 366:1607–1621CrossRef

40.

Zeymer U, Gitt AK, Jünger C et al (2006) Acute Coronary Syndromes (ACOS) registry investigators. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 27(22):2661–2666PubMedCrossRef

41.

Ho PM, Tsai TT, Maddox TM et al (2010) Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care. Circ Cardiovasc Qual Outcomes 3(3):261–266PubMedCrossRef

42.

Iakovou I, Schmidt T, Bonizzoni E et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17):2126–2130PubMedCrossRef

43.

Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373(9665):723–731PubMedCrossRef

44.

Spertus JA, Kettelkamp R, Vance C et al (2006) Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113(24):2803–2809PubMedCrossRef

45.

Mehta SR, Tanguay JF, Eikelboom JW et al (2010) CURRENT-OASIS 7 Trial Investigators double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376(9748):1233–1243PubMedCrossRef

46.

Wright RS, Anderson JL, Adams CD et al (2011) 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline). J Am Coll Cardiol 57(19):e215–367PubMedCrossRef

47.

Geisler T, Gawaz M, Steinhubl SR et al (2010) Current strategies in antiplatelet therapy – does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease? Pharmacol Ther 127(2):95–107PubMedCrossRef

48.

Zürn CS, Geisler T, Gawaz M (2010) ADP-receptor blockade: a case for personalised pharmacotherapy? Thromb Haemost 103(3):496–506PubMedCrossRef

49.

Brandt JT, Payne CD, Wiviott SD et al (2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153(1):66.e9–16PubMedCrossRef

50.

Wiviott SD, Trenk D, Frelinger AL et al (2007) PRINCIPLE-TIMI 44 Investigators. Circulation 116(25):2923–2932PubMedCrossRef

51.

Varenhorst C, James S, Erlinge D et al (2009) Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in ASS-treated patients with coronary artery disease. Eur Heart J 30(14):1744–1752PubMedCrossRef

52.

Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015PubMedCrossRef

53.

Wiviott SD, Braunwald E, Angiolillo DJ et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – Thrombolysis In Myocardial Infarction 38. Circulation 118(16):1626–1636PubMedCrossRef

54.

Wallentin L, Becker RC, Budaj A et al (2009) PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057PubMedCrossRef

55.

Di Girolamo G, Czerniuk P, Bertuola R, Keller GA (2010) Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. Clin Ther 32(1):161–170CrossRef

56.

Kim SD, Kang W, Lee HW et al (2009) Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Clin Ther 31(4):793–803PubMedCrossRef

57.

Sibbing D, Braun S, Morath T et al (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53(10):849–856PubMedCrossRef

58.

Geisler T, Zürn C, Simonenko R et al (2010) Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 31(1):59–66PubMedCrossRef

59.

Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11):1097–1105PubMedCrossRef

60.

Price MJ, Angiolillo DJ, Teirstein PS et al (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124(10):1132–1137PubMedCrossRef

61.

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm

62.

Mega JL, Simon T, Collet JP et al (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16):1821–1830PubMedCrossRef

63.

Geisler T, Bigalke B, Schwab M (2011) CYP2C19 genotype and outcomes of clopidogrel treatment. N Engl J Med 364(5):481–482PubMedCrossRef

64.

Levine GN, Bates ER, Blankenship JC et al. (2011) 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58(24):e44–122PubMedCrossRef

65.

Valgimigli M, Campo G, Monti M et al for the Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) (2012) Short versus long-term duration of dual antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125(16):2015–2026PubMedCrossRef

66.

Trenk D, Stone GW, Gawaz M et al (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol [Epub ahead of print]

Titel: Update orale Plättchenhemmer
Positionspapier der deutschen Gesellschaft für Kardiologie
verfasst von: Prof. Dr. M. Gawaz
PD Dr. T. Geisler
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Die Kardiologie / Ausgabe 3/2012
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI: https://doi.org/10.1007/s12181-012-0419-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Kann die Indikation zur Antikoagulation durch die Katheterablation von Vorhofflimmern ersetzt werden?

Interventionelle Behandlung der Aortenisthmusstenose im Erwachsenenalter

Belastungsdyspnoe durch Impression des linken Vorhofs

Vareniclin – Erhöhtes kardiovaskuläres Risiko bei der Raucherentwöhnung?

Erratum zu: Konsensusempfehlungen der DRG/DGK/DGPK zum Einsatz der Herzbildgebung mit Computertomographie und Magnetresonanztomographie